Wannachai Sakuludomkan

Wannachai Sakuludomkan

Auto-generated profile, based on publicly available information

Wannachai Sakuludomkan

Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
WSWannachai Sakuludomkan
Wannachai Sakuludomkan
RKRapheephorn Khatsri
Rapheephorn Khatsri
NDNahathai Dukaew
Nahathai Dukaew
NKNapatsorn Kraivisitkul
Napatsorn Kraivisitkul
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Background: Although angiotensin-converting enzyme (ACE) inhibitors are among the most-prescribed medications in the world, the extent to which they increase the risk of adverse effects remains uncertain. This study aimed to systematically determine the adverse effects of ACE inhibitors versus placebo across a wide range of therapeutic settings. Methods: Systematic searches were conducted on PubMed, Web of Science, and Cochrane Library databases. Randomized controlled trials (RCTs) comparing an ACE inhibitor to a placebo were retrieved. The relative risk (RR) and its 95% confidence interval (95% CI) were utilized as a summary effect measure. A random-effects model was used to calculate pooled-effect estimates. Results: A total of 378 RCTs fulfilled the eligibility criteria, with 257 RCTs included in the meta-analysis. Compared with a placebo, ACE inhibitors were associated with an significantly increased risk of dry cough (RR = 2.66, 95% CI = 2.20 to 3.20, p < 0.001), hypotension (RR = 1.98, 95% CI = 1.66 to 2.35, p < 0.001), dizziness (RR = 1.46, 95% CI = 1.26 to 1.70, p < 0.001), and hyperkalemia (RR = 1.24, 95% CI = 1.01 to 1.52, p = 0.037). The risk difference was quantified to be 0.037, 0.030, 0.017, and 0.009, respectively. Conclusions: We quantified the relative risk of numerous adverse events associated with the use of ACE inhibitors in a variety of demographics. This information can help healthcare providers be fully informed about any potential adverse consequences and make appropriate suggestions for their patients requiring ACE inhibitor therapy.


7 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
PKPreeyaporn Klinjan
Preeyaporn Klinjan
WSWannachai Sakuludomkan
Wannachai Sakuludomkan
NDNahathai Dukaew
Nahathai Dukaew
RIRatchanon Inpan
Ratchanon Inpan
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Skin aging is one of the most concerning issues that occur after menopause. The Genistein Nutraceutical (GEN) product, containing genistein, vitamin E, vitamin B3, and ceramide, has been formulated as a topical anti-aging product for improving the health of postmenopausal women’s facial skin. This study aimed to investigate the efficacy and safety of the GEN product on postmenopausal women’s facial skin. This randomized, double-blind, placebo-controlled trial randomly assigned 50 postmenopausal women to receive either the GEN product (n = 25) or the placebo (PLA) product (n = 25), topically applied twice daily for 6 weeks. The outcome assessments included multiple skin parameters related to skin wrinkling, color, hydration, and facial skin quality at baseline and week 6. The percentage mean changes or absolute mean changes, where appropriate, in skin parameters were compared between the two groups. The mean age of the participants was 55.8 ± 3.4 years. For skin wrinkling and skin color parameters, only skin redness was significantly higher in the GEN group when compared to the PLA group. Following the application of the GEN product, skin hydration increased while fine pores and their area decreased. Subgroup analysis of older women (age ≥ 56 years) with adequate compliance found significant differences between the two groups in the percentage mean changes of most skin wrinkle parameters. The GEN product has benefits for the facial skin of postmenopausal women, particularly those who are older. It can moisturize facial skin, lessen wrinkles, and enhance redness.

27 March 2023 in Publications
Verified
Journal Article
Open access
PDF file
CSChompunuch Saravudecha
Chompunuch Saravudecha
DTDuangruthai Na Thungfai
Duangruthai Na Thungfai
CPChananthida Phasom
Chananthida Phasom
SGSodsri Gunta-In
Sodsri Gunta-In
AMAorrakanya Metha
Aorrakanya Metha
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Biomedical fields have seen a remarkable increase in hybrid Gold open access articles. However, it is uncertain whether the hybrid Gold open access option contributes to a citation advantage, an increase in the citations of articles made immediately available as open access regardless of the article’s quality or whether it involves a trending topic of discussion. This study aimed to compare the citation counts of hybrid Gold open access articles to subscription articles published in hybrid journals. The study aimed to ascertain if hybrid Gold open access publications yield an advantage in terms of citations. This cross-sectional study included the list of hybrid journals under 59 categories in the ‘Clinical Medicine’ group from Clarivate’s Journal Citation Reports (JCR) during 2018–2021. The number of citable items with ‘Gold Open Access’ and ‘Subscription and Free to Read’ in each journal, as well as the number of citations of those citable items, were extracted from JCR. A hybrid Gold open access citation advantage was computed by dividing the number of citations per citable item with hybrid Gold open access by the number of citations per citable item with a subscription. A total of 498, 636, 1009, and 1328 hybrid journals in the 2018 JCR, 2019 JCR, 2020 JCR, and 2021 JCR, respectively, were included in this study. The citation advantage of hybrid Gold open access articles over subscription articles in 2018 was 1.45 (95% confidence interval (CI), 1.24–1.65); in 2019, it was 1.31 (95% CI, 1.20–1.41); in 2020, it was 1.30 (95% CI, 1.20–1.39); and in 2021, it was 1.31 (95% CI, 1.20–1.42). In the ‘Clinical Medicine’ discipline, the articles published in the hybrid journal as hybrid Gold open access had a greater number of citations when compared to those published as a subscription, self-archived, or otherwise openly accessible option.

6 August 2021 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
WSWannachai Sakuludomkan
Wannachai Sakuludomkan
RYRanchana Yeewa
Ranchana Yeewa
SSSubhawat Subhawa
Subhawat Subhawa
CKChakkrit Khanaree
Chakkrit Khanaree
Arisa (Imsumran) BonnessArisa (Imsumran) Bonness
Arisa (Imsumran) Bonness
TCTeera Chewonarin
Teera Chewonarin
Houttuynia cordata Thunb. (plukaow in Thai language) exhibits several biological properties, and many products of H. cordata are therefore commercially available for human consumption, such as fermented juice or tablets as food supplements. This study aimed to investigate the antidiabetic effects of fermented H. cordata (HC) in high-fat diets and streptozotocin-induced diabetic rats. Oral administration of HC at a dose of 100mg/kg.bw not only maintained bodyweight, food intake, and water consumption but also reduced blood glucose levels and improved glucose tolerance ability in the diabetic rats. Moreover, HC also decreased oxidative stress markers in serum and inflammatory-related mediators in pancreas tissues, indicating the improvement of pancreatic beta-cell function in the diabetic rats. In order to clarify the mechanism of HC, the effects of ethanolic extract of HC (HCE) on insulin resistance were determined in 3T3-L1 adipocytes. FHE could recover glucose uptake and decrease lipolysis in palmitate-treated 3T3-L1 adipocytes. Taken together, these results demonstrate that HC can improve diabetic symptoms by enhancing insulin sensitivity, reducing oxidative stress, and suppressing inflammation.

14 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NDNahathai Dukaew
Nahathai Dukaew
PTPatcharawadee Thongkumkoon
Patcharawadee Thongkumkoon
NSNutnicha Sirikaew
Nutnicha Sirikaew
SDSivamoke Dissook
Sivamoke Dissook
WSWannachai Sakuludomkan
Wannachai Sakuludomkan
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Mycophenolic acid (MPA) and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed together in certain groups of patients, including solid organ transplant recipients. However, little is known about the pharmacokinetic drug–drug interactions (DDIs) between these two medications. Therefore, the present study aimed to determine the effects of TMP-SMX on MPA pharmacokinetics in humans and to find out the relationship between MPA pharmacokinetics and gut microbiota alteration. This study enrolled 16 healthy volunteers to take a single oral dose of 1000 mg mycophenolate mofetil (MMF), a prodrug of MPA, administered without and with concurrent use of TMP-SMX (320/1600 mg/day) for five days. The pharmacokinetic parameters of MPA and its glucuronide (MPAG) were measured using high-performance liquid chromatography. The composition of gut microbiota in stool samples was profiled using a 16S rRNA metagenomic sequencing technique during pre- and post-TMP-SMX treatment. Relative abundance, bacterial co-occurrence networks, and correlations between bacterial abundance and pharmacokinetic parameters were investigated. The results showed a significant decrease in systemic MPA exposure when TMP-SMX was coadministered with MMF. Analysis of the gut microbiome revealed altered relative abundance of two enriched genera, namely the genus Bacteroides and Faecalibacterium, following TMP-SMX treatment. The relative abundance of the genera Bacteroides, [Eubacterium] coprostanoligenes group, [Eubacterium] eligens group, and Ruminococcus appeared to be significantly correlated with systemic MPA exposure. Coadministration of TMP-SMX with MMF resulted in a reduction in systemic MPA exposure. The pharmacokinetic DDIs between these two drugs were attributed to the effect of TMP-SMX, a broad-spectrum antibiotic, on gut microbiota-mediated MPA metabolism.